Rupitasertib, our first-in-class double node PAM inhibitor EVX020, our first-in-class KIF20A inhibitor Latest news Evexta Bio Appoints Edith A. Perez as Scientific Advisor October 25, 2024 Evexta Bio appoints Shawn M. Leland as Chairman of the Board of Directors June 19, 2024 Evexta Bio Reports Progress towards Clinical Development of Rupitasertib in Advanced Breast Cancer April 22, 2024
Evexta Bio Reports Progress towards Clinical Development of Rupitasertib in Advanced Breast Cancer April 22, 2024
